Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSEIDON: Durvalumab and Tremelimumab in First-Line Metastatic NSCLC
NCT03164616Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2017
- Primary completion
- Mar 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Progression-Free Survival at 25 months and Overall Survival at 45 months. Started Jun 2017; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03164616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164616.